Breast carcinoma developing in patients on hormone replacement therapy: A histological and immunohistological study

Journal of Clinical Pathology

Volumn 51, Issue 12, 1998, Pages 935-938

  O'Connor, Isobel Fitzgerald ^a   Shembekar, Madhuri V ^a   Shousha, Sami ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Bcl 2; Breast carcinoma; E cadherin; Hormone replacement therapy; P53

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0032427232     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.12.935     Document Type: Article

References (15)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59.
2. Shousha S, Peston D. Immunohistochemical demonstration of oestrogen and progesterone receptors in paraffin sections of breast carcinoma. Curr Diagn Pathol 1997;4: 176-80.
3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991;19:403-10.
4. Magnusson C, Holmberg L, Norden T, et al. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996;38:325-34.
5. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11-17.
6. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997;79:1918-22.
7. Sannino P, Shousha S. Demonstration of oestrogen receptors in paraffin wax sections of breast carcinoma using the monoclonal antibody 1D5 and microwave oven processing. J Clin Pathol 1994;47:90-2.
8. Taylor CR. Paraffin section immunocytochemistry for estrogen receptor. The time has come. Cancer 1996;77: 2419-22.
9. Barbareschi M, Caffo O, Vernesi S, et al. Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up. Hum Pathol 1996;27:1149-55.
10. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
11. Domagala W, Harezga B, Szadowska A, et al. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol 1993;142:669-74.
12. Pratap R, Shousha S. Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumor grade and axillary lymph node status. Breast Cancer Res Treat 1998;49:35-9.
13. Sitonen SM, Kononen JT, Helin HJ, et al. Reduced E-cadherin expression is associated with invasiveness and favourable prognosis in breast cancer. Am J Clin Pathol 1996;105:394-402.
14. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993;142: 987-93.
15. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993;143:1731-42.